LinkedIn Icon
Sept 5 – 7 | San Diego

Last few passes remaining – secure your place today!

Day One
Thursday September 6, 2018

Day Two
Friday September 7, 2018

Morning Coffee & Registration

Chair’s Opening Remarks

  • James Wabby Executive Director - Regulatory Affairs, Devices & Combination Products, Allergan

Ensuring a Regulatory Compliant Injectable Device

Opening Address: How Safe Are My Devices? Regulatory Compliance for Different Types of Injectables

  • James Wabby Executive Director - Regulatory Affairs, Devices & Combination Products, Allergan


  • Regulatory expectations and differences for devices and drugs – from human factors to quality demonstrations
  • It’s not one-size-fits-all: adapting your approach and filing based on your injector for a smooth approval
  • Develop an effective regulatory inspection strategy and what feedback should you gather post-launch for surveillance?
  • Case studies to compare and contrast for open discussions

Combination Products Regulatory Expectations from the Agencies


  • Combination products approval guidelines – what data is required for filing?
  • Updates on CRF21 Part 4 – cGMP and multi-site manufacturing oversight

Speed Networking & Morning Refreshments

The Human Touch – Developing a User-Friendly Device for Your Patients

How to Anticipate the 2020 Deadline – EU Medical Device Directive

  • Gay Steinbrick Lead Medical Device & Combination Products, Global Safety, Merck


  • Key changes with MEDDEV Rev 4
  • Looking ahead to EU MDR
  • Clinical evaluation reports for drug delivery device constituents

The New Beginning after Launch – A Device Regulatory Perspective and Journey


  • Post-launch regulatory considerations and executing a robust change system for device
  • Regulatory affairs’ role during the evolution of injectable devices – from PFS to on-body injector
  • Case study: Amgen’s success story and lesson learned

Tech-Show at Exhibition Hall


  • Live demos from our technology partners to showcase how latest PFS and injectable innovations.
  • Delegates will get the chance to ask questions during this interactive sessions.

Lunch & Networking

Human Factors Study – How, When, What and Who?

  • Young Chun Principal Engineer – Human Factors Lead, Shire


  • It’s not a check box exercise: devising a thorough design plan for your HF study
  • When should you conduct and what’s the optimal sample size?
  • Defining your sample pool for a meaningful study

Human Factors within the Device Design Control Paradigm

  • Nick Zampa Senior Engineer, Technical Development Human Factors & Risk Management, Biogen


  • How can a human factors approach enable more robust risk management?
  • Knowing your intended users to make risk-based decisions about device design.
  • Integrating human factors as part of the broader device development process within Pharma/Bio-Pharma
  • Post-launch: role of human factors during post-market surveillance?

A Different Perspective – Biosimilars Combination Product Development Considerations and Challenges?

  • Alasdair Young Associate Director - Device Engineering , Coherus BioSciences


  • Biosimilars and interchangeability:
    • A perspective on current human factors guideline
    • The impact on technology selection
  • Developing a biosimilar as a combination product
    • Anticipating and addressing potential challenges with characterizing a reference product
    • Differentiation – managing technology platform across products

Panel Discussion: Applying Human Factors Engineering to Platform Drug Delivery Devices – Pitfalls and Lessons Learned

  • Allison Strochlic Research Director, Human Factors Engineering, UL
  • E Guan Director, R&D, Platform Device Development, MedImmune
  • Raihan Hossain Associate Director CH I&D Medical Device Quality, Bayer
  • Sara Waxberg McNew Director, Human Factors & Industrial Design, Delivery Device R&D, Eli Lilly & Company


The panel will discuss various topics related to applying HFE to platform drug delivery devices, including:

  • How to select a platform device that reflects strong HFE, including how to perform HFE-focused “due diligence” on potential platform device manufacturers
  • How to properly scale HFE work for a particular drug and indication, leveraging any prior HFE work performed on the platform
  • Potential opportunities to “bridge” usability test data and HFE end-products between platform devices, thereby reducing the extent of usability testing needed for specific products and indications in development

     At the end of this session, delegates will also have the opportunity to fire Qs for our elite panelists.

Afternoon Refreshments & Networking

Device Development Using In-Silico Techniques within an FDA Framework


  • Solving some of the industry’s most complex device design challenges using In-Silico (virtual) techniques
  • Reporting of computational modelling within an FDA regulatory submission – FDA V&V40
  • Digital evidence and the digital twin
  • Acoustic design and simulation
  • Will modelling and simulation ever be accepted as credible evidence of safety or clinical benefit?

Less is More – Delivering a High Volume, Highly Viscosity Drug with Precise Dosage

  • Amy Wang Director Drug Delivery & Device Development, Alexion Pharma


  • With trends turning towards less frequent administration and larger dosing, what does it mean to existing formulation and drug delivery options?
  • Addressing the challenges of highly concentrated and highly viscous drugs during injection
  • Different platform selection criteria and considerations
  • Challenges to work with confined parameters and lessons learned

Downsizing: Microneedle Opportunity in Injectables


  • How micro can a microneedle injectable be?
  • Formulation and efficacy challenges
  • Applications and opportunities – patient adherence and ease of self administration

Chair’s Closing Remarks

  • James Wabby Executive Director - Regulatory Affairs, Devices & Combination Products, Allergan

Close of Day 1